{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:40Z","timestamp":1791248080014,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical effects of underweight status on short-term treatment-related morbidity in patients receiving curative-intent anticancer therapy remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational cohort study using a comprehensive oncology database, including 2,504 consecutive patients with histologically confirmed malignancies treated between March 1 and June 30, 2020, at major cancer centers and outpatient clinics across Saudi Arabia. Patients who received curative-intent outpatient systemic anticancer therapy were eligible. Underweight (body mass index [BMI]\u2009&lt;\u200918.5\u00a0kg\/m\u00b2) and normal-weight patients were compared with respect to baseline characteristics, treatment patterns, and 30-day morbidity. Multivariable logistic regression was used to identify factors independently associated with morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 787 patients met the eligibility criteria and were included in the analysis. Underweight patients were more frequently male (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas age (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.764) and Eastern Cooperative Oncology Group (ECOG) performance status (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.152) were similar between the BMI groups. Cancer stage distribution and curative treatment approach (neoadjuvant vs. adjuvant) did not differ significantly. Underweight patients were more likely to receive intravenous therapy (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005) and less likely to receive hormonal or targeted therapy. In unadjusted analyses, underweight patients had higher 30-day morbidity, with increased hospitalization (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023), emergency department visits (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034), and chemotherapy dose reductions (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). After multivariable adjustment, underweight BMI was not independently associated with morbidity, whereas poorer ECOG performance status and treatment class were the strongest predictors. Intensive care unit admission rates did not differ between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Underweight status was associated with increased unadjusted short-term treatment-related morbidity among patients receiving curative-intent anticancer therapy. However, this association was largely explained by functional status and treatment-related factors. These findings highlight the importance of early risk stratification and proactive supportive care rather than BMI alone to optimize treatment tolerance in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16499-w","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:37:39Z","timestamp":1783690659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of underweight on patients receiving curative-intent anticancer therapy: analysis of a large oncology database in Saudi Arabia"],"prefix":"10.1186","volume":"26","author":[{"given":"Emad","family":"Tashkandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"16499_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA. Cancer J. Clin., vol. 71, no. 3, pp. 209\u2013249, May 2021. https:\/\/doi.org\/10.3322\/CAAC.21660","DOI":"10.3322\/CAAC.21660"},{"key":"16499_CR2","doi-asserted-by":"publisher","unstructured":"Aseafan M, et al. Population-based survival for cancer patients in Saudi Arabia for the years 2005\u20132009. Sci Rep. Dec. 2022;12(1). https:\/\/doi.org\/10.1038\/S41598-021-04374-6.","DOI":"10.1038\/S41598-021-04374-6"},{"key":"16499_CR3","doi-asserted-by":"publisher","unstructured":"Tran KB, et al. The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. Aug. 2022;400:563\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(22)01438-6.","DOI":"10.1016\/S0140-6736(22)01438-6"},{"key":"16499_CR4","doi-asserted-by":"publisher","unstructured":"Petrelli F, et al. Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Netw open. Mar. 2021;4(3). https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2021.3520.","DOI":"10.1001\/JAMANETWORKOPEN.2021.3520"},{"key":"16499_CR5","doi-asserted-by":"publisher","unstructured":"Simillis C et al. Sep., A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer, Eur. J. Cancer, vol. 172, pp. 237\u2013251, 2022, https:\/\/doi.org\/10.1016\/j.ejca.2022.05.020","DOI":"10.1016\/j.ejca.2022.05.020"},{"key":"16499_CR6","doi-asserted-by":"publisher","unstructured":"Kim LH, Doan P, He Y, Lau HM, Pleass H, Patel MI. A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes, J. Urol., vol. 205, no. 2, pp. 346\u2013355, Feb. 2021, https:\/\/doi.org\/10.1097\/JU.0000000000001377","DOI":"10.1097\/JU.0000000000001377"},{"key":"16499_CR7","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni J, Zhang L. Cancer Cachexia: Definition, Staging, and Emerging Treatments. Cancer Manag Res. 2020;12:5597. https:\/\/doi.org\/10.2147\/CMAR.S261585.","journal-title":"Cancer Manag Res"},{"key":"16499_CR8","doi-asserted-by":"publisher","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia, Nat. Rev. Dis. Prim. 2018 41, vol. 4, no. 1, pp. 1\u201318, Jan. 2018. https:\/\/doi.org\/10.1038\/nrdp.2017.105","DOI":"10.1038\/nrdp.2017.105"},{"key":"16499_CR9","doi-asserted-by":"publisher","unstructured":"Arends J, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines\u2606. ESMO open. Jun. 2021;6(3). https:\/\/doi.org\/10.1016\/J.ESMOOP.2021.100092.","DOI":"10.1016\/J.ESMOOP.2021.100092"},{"key":"16499_CR10","doi-asserted-by":"publisher","unstructured":"Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Cancer Cachexia: Its Mechanism and Clinical Significance, Int. J. Mol. Sci., vol. 22, no. 16, Aug. 2021, https:\/\/doi.org\/10.3390\/IJMS22168491","DOI":"10.3390\/IJMS22168491"},{"key":"16499_CR11","doi-asserted-by":"publisher","unstructured":"Marshall KM, Loeliger J, Nolte L, Kelaart A, Kiss NK. Prevalence of malnutrition and impact on clinical outcomes in cancer services: A comparison of two time points. Clin Nutr. Apr. 2019;38(2):644\u201351. https:\/\/doi.org\/10.1016\/J.CLNU.2018.04.007.","DOI":"10.1016\/J.CLNU.2018.04.007"},{"key":"16499_CR12","doi-asserted-by":"publisher","unstructured":"Alessy SA, AlWaheidi S. Moving cancer prevention and care forward in Saudi Arabia. J Cancer Policy. Dec. 2020;26:100250. https:\/\/doi.org\/10.1016\/J.JCPO.2020.100250.","DOI":"10.1016\/J.JCPO.2020.100250"},{"key":"16499_CR13","doi-asserted-by":"publisher","unstructured":"Phelps NH et al. Mar., Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults, Lancet, vol. 403, no. 10431, pp. 1027\u20131050, 2024, https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","DOI":"10.1016\/S0140-6736(23)02750-2"},{"key":"16499_CR14","doi-asserted-by":"publisher","unstructured":"Hosseini SM et al. Prevalence of severe malnutrition in cancer patients: a systematic review and meta-analysis, J. Heal. Popul. Nutr. 2025 441, vol. 44, no. 1, p. 252-, Jul. 2025. https:\/\/doi.org\/10.1186\/S41043-025-01006-X","DOI":"10.1186\/S41043-025-01006-X"},{"issue":"4","key":"16499_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/MCO.2021.2244","volume":"14","author":"E Tashkandi","year":"2021","unstructured":"Tashkandi E, et al. Mortality and morbidity of curative and palliative anticancer treatments during the COVID-19 pandemic: A multicenter population-based retrospective study. Mol Clin Oncol. 2021;14(4):1\u201311. https:\/\/doi.org\/10.3892\/MCO.2021.2244.","journal-title":"Mol Clin Oncol"},{"key":"16499_CR16","doi-asserted-by":"publisher","unstructured":"Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Int J Surg. Dec. 2014;12(12):1500\u201324. https:\/\/doi.org\/10.1016\/J.IJSU.2014.07.014.","DOI":"10.1016\/J.IJSU.2014.07.014"},{"key":"16499_CR17","doi-asserted-by":"publisher","unstructured":"Sun M et al. Oct., Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: the Obesity and Disease Development Sweden (ODDS) pooled cohort study, Lancet Reg. Heal. Eur., vol. 45, 2024, https:\/\/doi.org\/10.1016\/J.LANEPE.2024.101034","DOI":"10.1016\/J.LANEPE.2024.101034"},{"key":"16499_CR18","doi-asserted-by":"publisher","unstructured":"Gebremedhin TK, Cherie A, Tolera BD, Atinafu BT, Demelew TM. Prevalence and risk factors of malnutrition among adult cancer patients receiving chemotherapy treatment in cancer center, Ethiopia: cross-sectional study. Heliyon. Jun. 2021;7(6). https:\/\/doi.org\/10.1016\/J.HELIYON.2021.E07362.","DOI":"10.1016\/J.HELIYON.2021.E07362"},{"key":"16499_CR19","doi-asserted-by":"publisher","unstructured":"Tu H, et al. Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer. Innov (Cambridge. Nov. 2022;3(6). https:\/\/doi.org\/10.1016\/J.XINN.2022.100344.","DOI":"10.1016\/J.XINN.2022.100344"},{"key":"16499_CR20","doi-asserted-by":"publisher","unstructured":"Grabowski JP, Richter R, Rittmeister H, Chekerov R, Woopen H, Sehouli J. Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients. Anticancer Res. Oct. 2018;38(10):5853\u20138. https:\/\/doi.org\/10.21873\/ANTICANRES.12927.","DOI":"10.21873\/ANTICANRES.12927"},{"key":"16499_CR21","doi-asserted-by":"publisher","unstructured":"Shaw C, et al. Modification of systemic anti-cancer therapies and weight loss, a population-level real-world evidence study. Ther Adv Med Oncol. 2020;12. https:\/\/doi.org\/10.1177\/1758835920982805. WGROUP:STRING:PUBLICATION.","DOI":"10.1177\/1758835920982805"},{"key":"16499_CR22","unstructured":"Kim J, Jesus OD. Medicatio n Routes of Administration. StatPearls; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568677\/."},{"key":"16499_CR23","doi-asserted-by":"publisher","unstructured":"Al-Jawaldeh A, et al. A Review on the Multidisciplinary Approach for Cancer Management in the Eastern Mediterranean Region: A Focus on Nutritional, Lifestyle and Supportive Care. Int J Environ Res Public Health. Apr. 2025;22(4):639. https:\/\/doi.org\/10.3390\/IJERPH22040639.","DOI":"10.3390\/IJERPH22040639"},{"key":"16499_CR24","doi-asserted-by":"publisher","unstructured":"Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults, Lancet (London, England), vol. 384, no. 9945, pp. 755\u2013765, Aug. 2014, https:\/\/doi.org\/10.1016\/S0140-6736(14)60892-8","DOI":"10.1016\/S0140-6736(14)60892-8"},{"key":"16499_CR25","doi-asserted-by":"publisher","unstructured":"Bong JW, et al. Nomogram for predicting the overall survival of underweight patients with colorectal cancer: a clinical study. BMC Gastroenterol. Dec. 2023;23(1). https:\/\/doi.org\/10.1186\/S12876-023-02669-8.","DOI":"10.1186\/S12876-023-02669-8"},{"key":"16499_CR26","doi-asserted-by":"publisher","unstructured":"Shahjehan F, Merchea A, Cochuyt JJ, Li Z, Colibaseanu DT, Kasi PM. Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer, Front. Oncol., vol. 8, no. DEC, 2018, https:\/\/doi.org\/10.3389\/FONC.2018.00620","DOI":"10.3389\/FONC.2018.00620"},{"key":"16499_CR27","doi-asserted-by":"publisher","unstructured":"Guarnieri  T et al. Jan., Eastern Cooperative Oncology Group Performance Status Scale as a Screening Tool for Sarcopenia in Onco-Hematology Patients, Brazilian J. Oncol., vol. 21, no. CP, 2025, https:\/\/doi.org\/10.1055\/S-0045-1802972","DOI":"10.1055\/S-0045-1802972"},{"key":"16499_CR28","doi-asserted-by":"publisher","unstructured":"de la Torre-Montero JC, et al. Nutritional Status in Locally Advanced or Metastatic Solid Cancer Patients Treated With Chemotherapy, Radiotherapy, and Immunotherapy in Spanish Outpatient Oncology Units. Semin Oncol Nurs. Feb. 2025;41(1):151801. https:\/\/doi.org\/10.1016\/J.SONCN.2024.151801.","DOI":"10.1016\/J.SONCN.2024.151801"},{"key":"16499_CR29","doi-asserted-by":"publisher","unstructured":"Bonomi PD, Walsh D, Currow DC, Ballinari G, Skipworth RJE. Cancer cachexia impact on chemotherapy dose reduction, treatment discontinuation, and survival: A qualitative systematic review., J. Clin. Oncol., vol. 40, no. 16_suppl, pp. e24103\u2013e24103, Jun. 2022, https:\/\/doi.org\/10.1200\/JCO.2022.40.16_SUPPL.E24103","DOI":"10.1200\/JCO.2022.40.16_SUPPL.E24103"},{"key":"16499_CR30","doi-asserted-by":"publisher","unstructured":"da Silva CMD, Besen BAMP, Nassar AP. Characteristics of critically ill patients with cancer associated with intensivist\u2019s perception of inappropriateness of ICU admission: A retrospective cohort study. J Crit Care. Feb. 2024;79:154468. https:\/\/doi.org\/10.1016\/J.JCRC.2023.154468.","DOI":"10.1016\/J.JCRC.2023.154468"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16499-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:18:47Z","timestamp":1791245927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16499-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16499"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16499-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5424867\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of King Abdullah Medical City (KAMC), Makkah, Saudi Arabia (IRB number 24-1328; November 24, 2024). Informed consent was not obtained due to the retrospective nature of the study and the use of routinely collected clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1196"}}